Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: Treatment implications

Current Pharmaceutical Design

Volumn 20, Issue 23, 2014, Pages 3812-3847

  Anderson, George ^a   Maes, Michael ^b  

^a CRC   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

AHr; Antioxidants; Circadian; Depression; Inflammation; Kynurenine; Nitrosative; Oxidative; Sirtuins

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ACETYLSALICYLIC ACID; AGOMELATINE; ALPHA TOCOPHEROL; ANTIOXIDANT; BENZOIC ACID; BUSPIRONE; CITALOPRAM; CURCUMIN; DESIPRAMINE; EPIGALLOCATECHIN GALLATE; ESCITALOPRAM; ETAZOLATE; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; LAMOTRIGINE; MELATONIN; PLACEBO; QUERCETIN; RAMELTEON; RESVERATROL; SERTRALINE; THIOCTIC ACID; TRILOSTANE; TRYPTOPHAN; UBIDECARENONE; VENLAFAXINE; XENOBIOTIC AGENT; ZINC; NITROGEN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; COMORBIDITY; DEPRESSION; DNA DAMAGE; HUMAN; ILLNESS BEHAVIOR; IMMUNOMODULATION; INFLAMMATION; LIPID MEMBRANE; MAJOR DEPRESSION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PUERPERAL DEPRESSION; ADAPTIVE IMMUNITY; ANIMAL; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIOXIDANTS; APOPTOSIS; AUTOIMMUNITY; DEPRESSION; HUMANS; IMMUNITY, CELLULAR; NEURONS; NITROGEN; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; TRYPTOPHAN;

EID: 84896725752     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660738     Document Type: Article

References (396)

1. [1] Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2): 764-85.
2. [2] Maes M, Maes L, Schotte C, et al. Clinical subtypes of unipolar depression: Part III. Quantitative differences in various biological markers between the cluster-analytically generated nonvital and vital depression classes. Psychiatry Res 1990, 34(1): 59-75
3. [3] Maes M: Functional" or "psychosomatic" symptoms, e.g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett 2009, 30(5): 564-73
4. [4] Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatr Res, 2012; 196(23): 243-49.
5. [5] Anderson G, Maes M, Berk M. Biological Underpinnings of the Commonalities in Depression, Somatization, and Chronic Fatigue Syndrome. Med Hypotheses 2012; 78: 752-56
6. [6] Alexandrino-Silva C, Wang YP, Carmen Viana M, Bulhões RS, Martins SS, Andrade LH. Gender differences in symptomatic profiles of depression: Results from the São Paulo Megacity Mental Health Survey. J Affect Disord 2013 May; 147(1-3): 355-64.
7. [7] van Loo HM, de Jonge P, Romeijn JW, Kessler RC, Schoevers RA. Data-driven subtypes of major depressive disorder: a systematic review. BMC Med 2012; 10: 156.
8. [8] Rausch JL, Johnson ME, Corley KM, et al. Depressed patients have higher body temperature: 5-HT transporter long promoter region effects. Neuropsychobiology 2003; 47(3): 120-7.
9. [9] Szuba MP, Guze BH, Baxter LR Jr: Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects. Biol Psychiatry 1997; 42(12): 1130-7.
10. [10] Charlton BG: The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypothes 2000; 54(1): 126-30.
11. [11] Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Medicine 2012; 10: 66
12. [12] Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog NeuroPsychopharmacol Biol Psychiatry 2011; 35(3): 769-83.
13. [13] Anderson G and Maes M. TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease. CNS Neurol Dis Drug Targets. In press.
14. [14] Anderson G, Beischlag TV, Vinciguerra M, Mazzoccoli G. The circadian clock circuitry and the AHR signaling pathway in physiology and pathology. Biochemical Pharmacology 2013; 85(10): 1405-16.
15. [15] Ng TP, Niti M, Fones C, Yap KB, Tan WC. Co-morbid association of depression and COPD: a population-based study. Respir Med 2009; 103(6): 895-901.
16. [16] Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67(3): 220-9.
17. [17] Wilken JA, Sullivan C. Recognizing and treating common psychiatric disorders in multiple sclerosis. Neurologist. 2007; 13(6): 343-54.
18. [18] Anderson G, Maes M. Postpartum Depression; Psychoneuroimmunological Underpinnings and Treatment. Neuropsychiatric Disease and Treatment 2013; 9: 277-87.
19. [19] De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003; 73(25): 3181-7.
20. [20] Milgrom J, Skouteris H, Worotniuk T, Henwood A, Bruce L. The association between ante-and postnatal depressive symptoms and obesity in both mother and child: a systematic review of the literature. Womens Health Issues 2012; 22(3): e319-28.
21. [21] Sivonova M, Zitnanova I, Hlincikova L, Skodacek I, Trebaticka J, Durackova Z. Oxidative stress in university students during examinations. Stress 2004; 7(3): 183-8.
22. [22] Maes M, Stevens WJ, Declerck LS, et al. Significantly increased expression of T-cell activation markers (interleukin-2 and HLADR) in depression: further evidence for an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17(2): 241-55.
23. [23] Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991; 84(4): 379-86.
24. [24] Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990-1991; 24(3): 115-20.
25. [25] Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20: 111-6.
26. [26] Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999; 85(3): 275-91.
27. [27] Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008; 29(3): 287-91.
28. [28] Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009; 30(4): 470-6.
29. [29] Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 2009; 30(6): 715-22.
30. [30] Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocinol Lett 2009; 30: 462-9.
31. [31] Witte ME, Geurts JJ, de Vries HE., van der Valk P, van Horssen J. Mitochondrial dysfunction: A potential link between neuroinflammation and neurodegeneration? Mitochondrion. 10: 411-8.
32. [32] Scapagnini G, Davinelli S, Drago F, De Lorenzo A, Oriani G. Antioxidants as antidepressants: fact or fiction? CNS Drugs 2012; 26(6): 477-90.
33. [33] Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18(5): 595-606.
34. [34] Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M. IgMmediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011; 135(1-3): 414-8.
35. [35] Ohmori H, Kanayama N. Immunogenicity of an inflammationassociated product, tyrosine nitrated self-proteins. Autoimmun Rev 2005; 4(4): 224-9.
36. [36] Maes M, De Vos N, Pioli R, et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000; 58(3): 241-6.
37. [37] Owen AJ, Batterham MJ, Probst YC, Grenyer BF, Tapsell LC. Low plasma vitamin E levels in major depression: diet or disease? Eur J Clin Nutr 2005; 59(2): 304-6.
38. [38] Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N. Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 2006; 91(1): 63-70.
39. [39] Vatassery GT, Lai JC, DeMaster EG, Smith WE, Quach HT. Oxidation of vitamin E and vitamin C and inhibition of brain mitochondrial oxidative phosphorylation by peroxynitrite. J Neurosci Res 2004; 75(6): 845-53.
40. [40] Marí M, Morales A, Colell A, García-Ruiz C, Kaplowitz N, Fernández-Checa JC. Mitochondrial glutathione: Features, regulation and role in disease. Biochim Biophys Acta. In press.
41. [41] Lobato KR, Cardoso CC, Binfaré RW, et al. alpha-Tocopherol administration produces an antidepressant-like effect in predictive animal models of depression. Behav Brain Res 2010; 209(2): 249-59.
42. [42] Wilkins HM, Kirchhof D, Manning E, Joseph JW, Linseman DA. Mitochondrial Glutathione Transport is a Key Determinant of Neuronal Susceptibility to Oxidative and Nitrosative Stress. J Biol Chem 2013; 288(7): 5091-101
43. [43] Gegg ME, Beltran B, Salas-Pino S, et al. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 2003; 86(1): 228-37.
44. [44] Rathinam ML, Watts LT, Narasimhan M, Riar AK, Mahimainathan L, Henderson GI. Astrocyte mediated protection of fetal cerebral cortical neurons from rotenone and paraquat. Environ Toxicol Pharmacol 2012; 33(2): 353-60.
45. [45] Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-) : cystine supplier and beyond. Amino Acids 2012; 42(1): 231-46.
46. [46] Jackman NA, Uliasz TF, Hewett JA, Hewett SJ. Regulation of system x(c)(-)activity and expression in astrocytes by interleukin-1_: implications for hypoxic neuronal injury. Glia 2010 Nov 15; 58(15): 1806-15.
47. [47] Kigerl KA, Ankeny DP, Garg SK, et al. System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo. Exp Neurol 2012; 233(1): 333-41.
48. [48] Yan Z, Garg SK, Banerjee R. Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. J Biol Chem 2010 Dec 31; 285(53): 41525-32.
49. [49] Li Y, Xiao B, Qiu W, Yang L, Hu B, Tian X, Yang H. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. J Affect Disord 2010; 124(1-2): 68-75.
50. [50] Lai IK, Dhakal K, Gadupudi GS, et al. N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents. Toxicology 2012; 302(1): 25-33.
51. [51] Seo JS, Park JY, Choi J, et al. NADPH oxidase mediates depressive behavior induced by chronic stress in mice. J Neurosci 2012; 32(28): 9690-9.
52. [52] Looney JM, Childs HM. The lactic acid and glutathione content of the blood of schizophrenic patients. J Clin Invest 1934; 13: 963-8.
53. [53] Kodydková J, Vávrová L, Zeman M, et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009; 42(13-14): 1368-74.
54. [54] Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 2008; 62(4): 236-49.
55. [55] Kim HJ, Barajas B, Wang M, Nel AE. Nrf2 activation by sulforaphane restores the age-related decrease of T(H)1 immunity: role of dendritic cells. J Allergy Clin Immunol 2008; 121(5): 1255-61.
56. [56] Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 676-92.
57. [57] Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci 2008; 1147: 395-412.
58. [58] Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009; 30(4): 462-9.
59. [59] Forester BP, Zuo CS, Ravichandran C, et al. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol 2012; 25(1): 43-50.
60. [60] Aboul-Fotouh S. Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol Biochem Behav 2013; 104: 105-12.
61. [61] Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8(6): 365-70.
62. [62] Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009; 63(5): 639-45.
63. [63] Gautam M, Agrawal M, Gautam M, Sharma P, Gautam AS, Gautam S. Role of antioxidants in generalised anxiety disorder and depression. Indian J Psychiatry 2012; 54(3): 244-7.
64. [64] Ga_ecki P, Szemraj J, Bie_kiewicz M, Zboralski K, Ga_ecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24: 277-86.
65. [65] Bravo R, Matito S, Cubero J, et al. Tryptophan-enriched cereal intake improves nocturnal sleep, melatonin, serotonin, and total antioxidant capacity levels and mood in elderly humans. Age (Dordr). In press.
66. [66] Anderson G, Maes M. Melatonin: an Overlooked Factor in Schizophrenia and in the Inhibition of Anti-Psychotic Side Effects. Metabolic Brain Disease 2012; 27(2): 113-9
67. [67] Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012; 21(18): 4030-7.
68. [68] Khaleghipour S, Masjedi M, Ahade H, et al, Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study. Sao Paulo Med J 2012; 130(3): 167-72.
69. [69] Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34(4): 348-57.
70. [70] Yalcin A, Kilinc E, Kocturk S, Resmi H, Sozmen EY. Effect of melatonin cotreatment against kainic acid on coenzyme Q10, lipid peroxidation and Trx mRNA in rat hippocampus. Int J Neurosci 2004; 114(9): 1085-97.
71. [71] Galecka E, Szemraj J, Florkowski A, et al. Single nucleotide polymorphisms and mRNA expression for melatonin MT(2) receptor in depression. Psychiatry Res 2011; 189(3): 472-4.
72. [72] Kripke DF, Nievergelt CM, Tranah GJ, et al. Polymorphisms in melatonin synthesis pathways: possible influences on depression. J Circadian Rhythms 2011; 9: 8.
73. [73] Jang SW, Liu X, Pradoldeja S, et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Nat Acad Sc 2010; 107(8): 3876-81
74. [74] Tosini G, Ye K, Iuvone PM. N-acetylserotonin: neuroprotection, neurogenesis, and the sleepy brain. Neuroscientist 2012; 18(6): 645-53.
75. [75] Stuss M, Wiktorska JA, Sewerynek E. N-acetylserotonin reduces lipopolysaccharide-induced lipid peroxidation in vitro more effectively than melatonin. Neuroendocrinol Lett 2010; 31(4): 489-96
76. [76] Mayo JC, Sainz RM, Tan D-X, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol 2005: 165: 139-49.
77. [77] Hardeland R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J Exp Integr Med 2011; 1(2): 67-81
78. [78] Mukda S, Møller M, Ebadi M, Govitrapong P. The modulatory effect of substance P on rat pineal norepinephrine release and melatonin secretion. Neurosci Lett 2009 Sep 25; 461(3): 258-61.
79. [79] Pontes GN, Cardoso, EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res 2007; 43: 365-71.
80. [80] Ren S, Correia MA. Heme: A regulator of rat hepatic tryptophan 2,3-dioxygenase. Arch Biochem Biophys 2000; 377(1): 195-203.
81. [81] Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF- B and Nrf2 cascades. J Pineal Res 2011; 50(2): 124-31
82. [82] Maes M, Fiar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012; 20(3): 127-50.
83. [83] Milczarek R, Hallmann A, Soko_owska E, Kaletha K, Klimek J. Melatonin enhances antioxidant action of alpha-tocopherol and ascorbate against NADPH-and iron-dependent lipid peroxidation in human placental mitochondria. J Pineal Res 2010; 49(2): 149-55.
84. [84] García JJ, Piñol-Ripoll G, Martínez-Ballarín E, et al. Melatonin reduces membrane rigidity and oxidative damage in the brain of SAMP(8) mice. Neurobiol Aging 2011; 32(11): 2045-54.
85. [85] Agil A, Navarro-Alarcon M, Ruiz R, Abuhamadah S, El-Mir M-Y, Vazquez GF. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J. Pineal Res 2011; 50: 207-12
86. [86] Wang S, Tian Y, Song L, et al. Exacerbated mechanical hyperalgesia in rats with genetically predisposed depressive behavior: role of melatonin and NMDA receptors. Pain 2012; 153(12): 2448-57.
87. [87] Liu YJ, Zhuang J, Zhu HY, Shen YX, Tan ZL, Zhou JN. Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J Pineal Res 2007; 43(3): 232-8.
88. [88] Muxel SM, Pires-Lapa MA, Monteiro AWA, et al. NF-kB Drives the Synthesis of Melatonin in RAW 264.7 Macrophages by Inducing the Transcription of the Arylalkylamine-N-Acetyltransferase (AA-NAT) Gene. PLoS ONE 2012; 7(12): e52010.
89. [89] Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008; 15(2): 93-101.
90. [90] Chen Y, Jiang T, Chen P, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res 2011; 188(2): 224-30.
91. [91] Monaco-Shawver L, Schwartz L, Tuluc F, et al. Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol 2011; 89(1): 113-25.
92. [92] Anacker C, Cattaneo A, Luoni A, et al. Glucocorticoid-Related Molecular Signaling Pathways Regulating Hippocampal Neurogenesis. Neuropsychopharmacol. In press.
93. [93] Huang TT, Zou Y, Corniola R. Oxidative stress and adult neurogenesis--effects of radiation and superoxide dismutase deficiency. Semin Cell Dev Biol 2012; 23(7): 738-44.
94. [94] Eisch AJ, Petrik D. Depression and hippocampal: neurogenesis: a road to remission? Science 2012; 338(6103): 72-5.
95. [95] Tang SW, Helmeste D, Leonard B. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review. World J Biol Psychiatry 2012; 13(6): 402-12.
96. [96] Herbette S, Roeckel-Drevet P, Drevet JR. Seleno-independent glutathione peroxidases. More than simple antioxidant scavengers. FEBS J 2007; 274(9): 2163-80.
97. [97] Ceballos-Picot I, Trivier JM, Nicole A, Sinet PM, Thevenin M. Age-correlated modifications of copper-zinc superoxide dismutase and glutathione-related enzyme activities in human erythrocytes. Clin Chem 1992; 38(1): 66-70.
98. [98] Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004; 19(2): 89-95.
99. [99] Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: lower GPX activity as another pathway explaining the increased incidence of coronary artery disease in depression Neuro Endocrinol Lett 2011; 32(2): 133-40.
100. [100] Srivastava N, Barthwal MK, Dalal PK, et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002; 72(1): 45-52.
101. [101] Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in postmortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011; 14(1): 123-30.
102. [102] Teyssier JR, Ragot S, Chauvet-Gélinier JC, Trojak B, Bonin B. Expression of oxidative stress-response genes is not activated in the prefrontal cortex of patients with depressive disorder. Psychiatry Res 2011; 186(2-3): 244-7.
103. [103] Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009; 12(4): 441-5.
104. [104] Stefanescu C, Ciobica A. The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disord 2012; 143(1-3): 34-8.
105. [105] Novío S, Núñez MJ, Amigo G, Freire-Garabal M. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. Basic Clin Pharmacol Toxicol 2011; 109(5): 365-71.
106. [106] Moretti M, Colla A, de Oliveira Balen G, et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res 2012; 46(3): 331-40.
107. [107] Liu Y, Jia G, Gou L, et al. Antidepressant-like effects of tea polyphenols on mouse model of chronic unpredictable mild stress. Pharmacol Biochem Behav 2013; 104: 27-32
108. [108] Arent CO, Réus GZ, Abelaira HM, et al. Synergist effects of nacetylcysteine and deferoxamine treatment on behavioral and oxidative parameters induced by chronic mild stress in rats. Neurochem Int 2012; 61(7): 1072-80.
109. [109] Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11(4): 376-81.
110. [110] Anderson G, Rodriguez M. Multiple Sclerosis, Seizures and Anti-Epileptics: Role of IL-18, IDO and Melatonin. European J Neurology. 2011; 18(5): 680-5.
111. [111] Zou Y, Corniola R, Leu D, et al. Extracellular superoxide dismutase is important for hippocampal neurogenesis and preservation of cognitive functions after irradiation. Proc Natl Acad Sci U S A 2012; 109(52): 21522-7.
112. [112] Elchuri S, Oberley TD, Qi W, et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 2005; 24(3): 367-80.
113. [113] Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38(2): 247-52.
114. [114] Ga_ecki P, Kedziora J, Florkowski A, Ga_lecka E. Lipid peroxidation and copper-zinc superoxide dismutase activity in patients treated with fluoxetine during the first episode of depression. Psychiatr Pol 2007; 41(5): 615-24.
115. [115] Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidativeantioxidative systems. Hum Psychopharmacol 2007; 22(2): 67-73.
116. [116] Andreazza AC, Frey BN, Erdtmann B, et al. DNA damage in bipolar disorder. Psychiatry Res 2007; 153(1): 27-32.
117. [117] Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(5): 1284-90.
118. [118] Smaga I, Pomierny B, Krzy_anowska W, et al. N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39(2): 280-7.
119. [119] Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007; 100(1-3): 279-81.
120. [120] Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol Lett 2011; 32(1): 7-24
121. [121] Gaecki Pmigielski J, Florkowski A, Bobiska K, Pietras T, Szemraj J. Analysis of two polymorphisms of the manganese superoxide dismutase gene: Ile-58Thr and Ala-9Val in patients with recurrent depressive disorder. Psychiatry Res 2010; 179(1): 43-6.
122. [122] Ga_ecki P, Maes M, Florkowski A, et al. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 2011; 129(1-3): 175-82.
123. [123] Ga_ecki P, Ga_ecka E, Maes M, et al.The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 2012; 138(3): 360-6.
124. [124] Talarowska M, Ga_ecki P, Maes M, et al. Malondialdehyde plasma concentration correlates with declarative and working memory in patients with recurrent depressive disorder. Mol Biol Rep 2012; 39(5): 5359-66.
125. [125] Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand. In press.
126. [126] Gárate I, Garcia-Bueno B, Madrigal JL, et al. Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry 2013; 73(1): 32-43.
127. [127] Kubera M, Curzytek K, Duda W, et al. A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4months. Brain Behav Immun. In press.
128. [128] Eskan MA, Rose BG, Benakanakere MR, et al. TLR4 and S1P receptors cooperate to enhance inflammatory cytokine production in human gingival epithelial cells. Eur J Immunol 2008; 38(4): 1138-47.
129. [129] Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 2008; 102(8): 950-8.
130. [130] Giri RK, Selvaraj SK, Kalra VK. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 2003; 170(10): 5281-94.
131. [131] Zhou J, Zhang S, Zhao X, Wei T. Melatonin impairs NADPH Oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res 2008; 45(2): 157-65.
132. [132] Cordero MD, Díaz-Parrado E, Carrión AM, et al. Is inflammation a mitochondrial dysfunction-dependent event in Fibromyalgia? Antioxid Redox Signal 2013; 18(7): 800-7
133. [133] Tatsumi H, Nakase H, Kano K,Ikeda T. Mechanistic study of the autoxidation of reduced flavin and quinone compounds. J Electroanalytical Chem.1998: 443: 236-42.
134. [134] Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A 2008; 105(46): 18053-7.
135. [135] Chapman KE, Chatterjee S, Fisher AB. Oxidant-Mediated Signaling and Injury in Pulmonary Endothelium. In The Pulmonary Endothelium: Function in health and disease. Eds. Voelkel RF, Rounds S 2009 John Wiley & Sons, Ltd. ISBN: 978-0-470-72361-6
136. [136] Fornazari M, de Paula JG, Castilho RF, Kowaltowski AJ. Redox properties of the adenoside triphosphate-sensitive K+ channel in brain mitochondria. J Neurosci Res 2008; 86(7): 1548-56.
137. [137] Madesh M, Hawkins BJ, Milovanova T, et al. Selective role for superoxide in InsP3 receptor-mediated mitochondrial dysfunction and endothelial apoptosis. J Cell Biol 2005; 170: 1079-90.
138. [138] Zhao ZY, Luan P, Huang SX, et al. Edaravone Protects HT22 Neurons from H(2) O(2)-induced Apoptosis by Inhibiting the MAPK Signaling Pathway. CNS Neurosci Ther 2013; 19(3): 163-9.
139. [139] Duric V, Banasr M, Licznerski P, et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010; 16(11): 1328-32
140. [140] Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837-848.
141. [141] Hwang J, Hiwang H, Lee HW, Suk K. Microglia signaling as a target of donepezil.Neuropharmacology 2010; 58: 1122e1129
142. [142] Baune BT, Smith E, Reppermund S, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 2012; 37(9): 1521-30.
143. [143] Lehner C, Gehwolf R, Tempfer H, et al. Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid Redox Signal 2011; 15(5): 1305-23.
144. [144] Su HC, Ma CT, Yu BC, et al. Glycogen synthase kinase-3_regulates anti-inflammatory property of fluoxetine. Int Immunopharmacol 2012; 14(2): 150-6.
145. [145] Thimmulappa RK, Lee H, Rangasamy T, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006; 116: 984-95.
146. [146] Hou YC, Janczuk A, Wang PG. Current trends in the development of nitric oxide donors. Curr Pharm Des 1999; 5(6): 417-71.
147. [147] Lin X, Yang H, Zhou L, Guo Z. Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med 2011; 51(1): 97-106.
148. [148] Pinto VL, Brunini TM, Ferraz MR, Okinga A, Mendes-Ribeiro AC. Depression and cardiovascular disease: role of nitric oxid. Cardiovasc Hematol Agents Med Chem 2008; 6(2): 142-9.
149. [149] Savass HA, Herken H, Yürekli M, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002; 45(2): 57-61.
150. [150] Montezuma K, Biojone C, Lisboa SF, Cunha FQ, Guimarães FS, Joca SR. Inhibition of iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence. Neuropharmacology 2012; 62(1): 485-91.
151. [151] Talarowska M, Ga_ecki P, Maes M, et al. Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci Lett. 2012; 510(2): 127-31
152. [152] Kim YK, Paik JW, Lee SW, Yoon D, Han C, Lee BH. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1091-6.
153. [153] Suzuki E, Yoshida Y, Shibuya A, Miyaoka H. Nitric oxide involvement in depression during interferon-alpha therapy. Int J Neuropsychopharmacol 2003; 6(4): 415-9
154. [154] Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Ueda N, Nakamura J. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(8): 1451-3.
155. [155] Pinto VL, de Souza PF, Brunini TM, et al. Low plasma levels of Larginine, impaired intraplatelet nitric oxide and platelet hyperaggregability: implications for cardiovascular disease in depressive patients. J Affect Disord 2012; 140(2): 187-92.
156. [156] Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004; 56(2): 129-34.
157. [157] Gao SF, Qi XR, Zhao J, Balesar R, Bao AM, Swaab DF. Decreased NOS1 Expression in the Anterior Cingulate Cortex in Depression. Cereb Cortex. In press.
158. [158] Hu Y, Wu DL, Luo CX, et al. Hippocampal nitric oxide contributes to sex difference in affective behaviors. Proc Natl Acad Sci U S A 2012; 109(35): 14224-9.
159. [159] Karolewicz B, Szebeni K, Stockmeier CA, et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004; 91(5): 1057-66.
160. [160] Oliveira RM, Guimarães FS, Deakin JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008; 41(4): 333-41
161. [161] Bernstein HG, Heinemann A, Krell D, et al. Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus. Cell Mol Biol (Noisy-le-grand) 2005; 51(3): 279-84.
162. [162] Wang D, An SC, Zhang X. Prevention of chronic stress-induced depression-like behavior by inducible nitric oxide inhibitor. Neurosci Lett 2008; 433(1): 59-64.
163. [163] Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010; 210(1): 84-91.
164. [164] Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone, PR. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety-and depression-like behaviours in mice: focus on individual differences. Pharmaco. Biochem. Behav 2011; 98(1): 161-8.
165. [165] Silva R, Mesquita AR, Bessa J, et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008; 152(3): 656-69.
166. [166] Gigliucci V, Buckley KN, Nunan J, O'Shea K, Harkin A. A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test. Pharmacol Biochem Behav 2010; 94(4): 524-33.
167. [167] Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32(4): 653-8.
168. [168] Anttolainen M, Valsta LM, Alfthan G, Kleemola P, Salminen I, Tamminen M. Effect of extreme fish consumption on dietary and plasma antioxidant levels and fatty acid composition. Eur J Clin Nutr 1996; 50(11): 741-6.
169. [169] Vareka T, Vecka M, Jirak R, et al. Plasma fatty acid profile in depressive disorder resembles insulin resistance state. Neuro Endocrinol Lett 2012; 33 Suppl 2: 83-6.
170. [170] Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidationderived reactive carbonyls. Med Res Rev 2007; 27(6): 817-68.
171. [171] Michalakeas CA, Parissis JT, Douzenis A, et al. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. J Card Fail 2011; 17(9): 748-54.
172. [172] Dimopoulos N, Piperi C, Psarra V, Lea RW, Kalofoutis A. Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res 2008; 161(1): 59-66.
173. [173] Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11(5): 523-9.
174. [174] Shin Y, White BH, Uh M, Sidhu A. Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation. Brain Res 2003; 968(1): 102-13.
175. [175] Feng Z, Hu W, Marnett LJ, Tang MS. Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV-and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutat Res 2006; 601(1-2): 125-36
176. [176] Bohr VA, Stevnsner T, de Souza-Pinto NC. Mitochondrial DNA repair of oxidative damage in mammalian cells. Gene 2002; 286(1): 127-34.
177. [177] Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009; 27(2): 120-39.
178. [178] Irie M, Miyata M, Kasai H. Depression and possible cancer risk due to oxidative DNA damage. J Psychiatr Res 2005; 39(6): 553-60.
179. [179] Abdel-Wahab BA, Salama RH. Venlafaxine protects against stressinduced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol Biochem Behav 2011; 100(1): 59-65.
180. [180] Anderson G. Hemochromatosis and Bipolar Disorder. Gen Hosp Psychiatry 2012; 34(4): 433.
181. [181] Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006; 60(5): 432-5
182. [182] Teyssier JR, Chauvet-Gelinier JC, Ragot S, Bonin B. Up-regulation of leucocytes genes implicated in telomere dysfunction and cellular senescence correlates with depression and anxiety severity scores. PLoS One 2012; 7(11): e49677.
183. [183] Shaffer JA, Epel E, Kang MS, et al. Depressive symptoms are not associated with leukocyte telomere length: findings from the Nova Scotia Health Survey (NSHS95), a population-based study. PLoS One 2012; 7(10): e48318.
184. [184] Hoen PW, Rosmalen JG, Schoevers RA, Huzen J, van der Harst P, de Jonge P. Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-based sample. Psychol Med 2013; 43(4): 689-97
185. [185] Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. PLoS One 2011; 6(3): e17837.
186. [186] Elvsåshagen T, Vera E, Bøen E, et al. The load of short telomeres is increased and associated with lifetime number of depressive episodes in bipolar II disorder. J Affect Disord 2011; 135(1-3): 43-50.
187. [187] Suomalainen A, Majander A, Haltia M, et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest 1992; 90(1): 61-6.
188. [188] Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010; 125(1-3): 287-94
189. [189] Maes M, Ringel K, Kubera M, Berk M, Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012; 136(3): 386-92.
190. [190] Maes M, Kubera M, Mihaylova I, et al. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: Implications for the pathways to chronic depression and neuroprogression. J Affect Disord. In press.
191. [191] Pawlak K, Mysliwiec M, Pawlak D. Oxidized LDL to autoantibodies against oxLDL ratio-the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis 2012; 224(1): 252-7.
192. [192] Gounopoulos P, Merki E, Hansen LF, Choi SH, Tsimikas S. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol 2007; 55(6): 821-37.
193. [193] Kraml PJ, Syrovátka P, Poto_ková J, And_l M. The Oxidized Low-Density Lipoprotein/_2-Glycoprotein I Complex Is Associated with Abdominal Obesity in Healthy Middle-Aged Men. Ann Nutr Metab 2013; 62(1): 7-13.
194. [194] Maes M, Mihaylova I, Leunis JC. Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett 2007; 28(6): 861-7.
195. [195] Levine J, Rapaport A, Lev L, et al. Inositol treatment raises CSF inositol levels. Brain Res 1993; 627(1): 168-70.
196. [196] Ananthanarayanan B, Ni Q, Zhang J. Signal propagation from membrane messengers to nuclear effectors revealed by reporters of phosphoinositide dynamics and Akt activity. Proc Natl Acad Sci U S A 2005; 102(42): 15081-6.
197. [197] Akin D, Manier DH, Sanders-Bush E, Shelton RC. Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. Neuropsychopharmacol 2004; 29(11): 2081-7.
198. [198] Tatebayashi Y, Nihonmatsu-Kikuchi N, Hayashi Y, Yu X, Soma M, Ikeda K. Abnormal fatty acid composition in the frontopolar cortex of patients with affective disorders. Transl Psychiatry 2012; 2: e204.
199. [199] Geffard CM, Bodet D, Martinet Y, Dabadie M-P. Detection of the specific IgM and IgA circulating in sera of multiple sclerosis patients: interest and perspectives. Immuno-Analyse Biologie Specialisee 2002; 17: 302-10.
200. [200] Mettenburg JM, Benzinger TL, Shimony JS, Snyder AZ, Sheline YI. Diminished performance on neuropsychological testing in late life depression is correlated with microstructural white matter abnormalities. Neuroimage 2012; 60(4): 2182-90.
201. [201] Lin J-K, Chen K-J, Liu G-Y, Chu Y-R, Lin-Shiau S-Y. Nitration and hydoxylation of aromatic amino acid and guanine by the air pollutant peroxyacetyl nitrate. Chemico-Biological Interactions 2000; 127(3): 219-36.
202. [202] Maes M, Mihaylova I, Kubera M, Leunis JC. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett 2008; 29 (3): 313-9.
203. [203] Workman JL, Weber MD, Nelson RJ. Dietary arginine depletion reduces depressive-like responses in male, but not female, mice. Behav Brain Res 2011; 223(1): 81-7.
204. [204] Keser A, Balkan B, Gozen O, Kanit L, Pogun S. Hippocampal neuronal nitric oxide synthase (nNOS) is regulated by nicotine and stress in female but not in male rats. Brain Res 2011; 1368: 134-42.
205. [205] Wang DW, Zhou RB, Yao YM, et al. Stimulation of_7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. J Pharmacol Exp Ther 2010; 335(3): 553-61.
206. [206] Markus RP, Silva CL, Franco DG, Barbosa EM Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Ther 2010; 126(3): 251-62.
207. [207] Krishnaswamy A, Cooper E. Reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors through a highly conserved cysteine near the intracellular mouth of the channel: implications for diseases that involve oxidative stress. J Physiol 2012; 590(Pt 1): 39-47.
208. [208] van de Ven AC, Muntjewerff JW, Netea-Maier RT, et al. Association between thyroid function, thyroid autoimmunity, and state and trait factors of depression. Acta Psychiatr Scand 2012; 126(5): 377-84.
209. [209] Yeang HX, Hamdam JM, Al-Huseini LM, et al. Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. J Biol Chem 2012; 287(13): 10556-64.
210. [210] Lucas K, Maes M. The role of the Toll-like receptor 4 pathway in the pathophysiology of inflammation-related diseases caused by environmental factors: possible treatments targeting the TLR4 pathway. Mol Neurobiol. In press.
211. [211] Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. Association study of the interleukin-1 beta (C-511 T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacol 2003; 28: 1182-5.
212. [212] Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleuki n-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009; 14: 1095-104.
213. [213] Jun TY, Pae CU, Hoon-Han A, et al. Possible association between-G308A tumor necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003; 13: 179-81.
214. [214] Pae CU, Yu HS, Kim TS, et al. Monocyte chemoattractant protein-1 (MCP1) promoter-2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004; 127: 279-81.
215. [215] Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008; 13: 800-12.
216. [216] Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5
217. [217] Ballou LR, Chao CP, Holness MA. Barker SC, Raghow R. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem. 1992: 267: 20044-50
218. [218] Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002; 168: 2644-51.
219. [219] Reunanen N, Westermarck J, Hakkinen L, et al. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998; 273: 5137-45
220. [220] Chen CL, Lin CF, Chang WT, Huang WC, Teng CF, Lin YS. Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood 2008; 111: 4365-74
221. [221] Chen CC, Sun YT, Chen JJ, Chang YJ. Tumor necrosis factoralpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001; 59: 493-500
222. [222] Guo JY, Li CY, Ruan YP, et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009; 612: 54-60.
223. [223] Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-4.
224. [224] Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 2012; 27(4): 405-13.
225. [225] Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995; 269: 970-3.
226. [226] Su KP, Huang SY, Peng CY, et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alphainduced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010; 67(6): 550-7.
227. [227] Shimoda-Matsubayashi S, Matsumine H, Kobayashi T. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem Biophysic Res Comm 1996; 226: 561-5.
228. [228] Shimoda-Matsubayashi S, Hattori T, Matsumine H. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurology 1997; 49: 1257-61.
229. [229] Pae CU, Yoon SJ, Patkar A, et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism and mood disorders: a preliminary study. Prog Neuro-psychopharmacol Biol Psychiatry 2006; 30: 1326-9.
230. [230] Tagliari B, dos Santos TM, Cunha AA, et al. Chronic variable stress induces oxidative stress and decreases butyrylcholinesterase activity in blood of rats. J Neural Transm 2010; 117(9): 1067-76.
231. [231] Borgstahl GE, Parge HE, Hickey MJ, Johnson MJ, Boissinot M, Hallewell RA. Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. Biochemistry. 1996; 35: 4287-97.
232. [232] Yap YW, Whiteman M, Cheung NS. Chlorinative stress: an under appreciated mediator of neurodegeneration? Cell Signal 2007; 19: 219-28.
233. [233] Green PS, Mendez AJ, Jacob JS, et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004; 90: 724-33.
234. [234] van der Vliet A, Eiserich JP, Halliwell, B, Cross CE. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 1997; 272: 7617-25.
235. [235] Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271: 14412-20.
236. [236] Gaecki P, Szemraj J, Zboralski K, Florkowski A, Lewiski A. Relation between functional polymorphism of catalase gene (-262C N T) and recurrent depressive disorder. Neuro Endocrinol Lett 2009; 30(3): 357-62.
237. [237] Budni J, Zomkowski AD, Engel D, et al. Folic acid prevents depressive-like behavior and hippocampal antioxidant imbalance induced by restraint stress in mice. Exp Neurol 2013; 240: 112-21
238. [238] Fu X, Ji R, Dam J. Antifatigue effect of coenzyme Q10 in mice. J Med Food 2010; 13(1): 211-5.
239. [239] Anderson G. Neuronal-Immune Interactions in Mediating Stress Effects in the Etiology and Course of Schizophrenia: Role of the Amygdala in Developmental Co-ordination. Med Hypotheses 2011; 76: 54-60.
240. [240] Anderson G, Maes M, Berk M. Inflammation-related disorders in the tryptophan catabolite (TRYCAT) pathway in depression and somatization. Adv Protein Chemistry Structural Biol 2012; 88: 27-48 .
241. [241] Butler MG, Dasouki M, Bittel D, Hunter S, Naini A, DiMauro S. Coenzyme Q10 levels in Prader-Willi syndrome: comparison with obese and non-obese subjects. Am J Med Genet A 2003; 119(2): 168-71
242. [242] Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q__effect on clinical improvement. PLoS One 2012; 7(4): e35677.
243. [243] O'Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012; 10: 154
244. [244] Mabuchi H, Nohara A, Kobayashi J, et al. Hokuriku Lipid Research Group. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195(2): 182-9.
245. [245] Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 2005; 25(1-4): 147-52.
246. [246] Sanchez-Barcelo EJ, Mediavilla MD, Tan D-X, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-95.
247. [247] Gouin JP, Connors J, Kiecolt-Glaser JK, et al. Altered expression of circadian rhythm genes among individuals with a history of depression. J Affect Disord 2010; 126(1-2): 161-6.
248. [248] McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders. J Biol Rhythms 2012; 27(5): 339-52.
249. [249] Kondratov RV, Vykhovanets O, Kondratova AA, Antoch MP. Antioxidant N-acetyl-L-cysteine ameliorates symptoms of premature aging associated with the deficiency of the circadian protein BMAL1. Aging (Albany NY) 2009; 1(12): 979-87.
250. [250] Uchida Y, Hirayama J, Nishina H. A common origin: signaling similarities in the regulation of the circadian clock and DNA damage responses. Biol Pharm Bull 2010; 33(4): 535-44.
251. [251] Bunney BG, Bunney WE. Mechanisms of Rapid Antidepressant Effects of Sleep Deprivation Therapy: Clock Genes and Circadian Rhythms. Biol Psychiatry. In press.
252. [252] Shimomura K, Lowrey PL, Vitaterna MH, et al. Genetic suppression of the circadian Clock mutation by the melatonin biosynthesis pathway. Proc Natl Acad Sci U S A 2010; 107(18): 8399-403.
253. [253] Christ E, Pfeffer M, Korf HW, von Gall C. Pineal melatonin synthesis is altered in Period1 deficient mice. Neuroscience 2010; 171(2): 398-406.
254. [254] Cristòfol R, Porquet D, Corpas R, et al. Neurons from senescenceaccelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J Pineal Res 2012; 52(3): 271-81.
255. [255] Michán S, Li Y, Chou MM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 2010; 30(29): 9695-707.
256. [256] Kishi T, Yoshimura R, Kitajima T, et al. SIRT1 gene is associated with major depressive disorder in the Japanese population. J Affect Disord 2010; 126(1-2): 167-73.
257. [257] O'Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science 2008; 320: 949-53.
258. [258] Mukai M, Lin TM, Peterson RE, Cooke PS, Tischkau SA. Behavioral rhythmicity of mice lacking AHR and attenuation of lightinduced phase shift by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Rhythms 2008; 23: 200-10
259. [259] Kimura A, Naka T, Nakahama T, et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 2009; 2006: 2027-35
260. [260] Oesch-Bartlomowicz B, Oesch F. Role of cAMP in mediating AHR signaling. Biochem Pharmacol 2009; 77: 627-41.
261. [261] Mayati A, Levoin N, Paris H, et al. Induction of intracellular calcium concentration by environmental benzo(a)pyrene involves a_2-adrenergic receptor/adenylyl cyclase/Epac-1/inositol 1,4,5-trisphosphate pathway in endothelial cells. J Biol Chem 2012; 287: 4041-52.
262. [262] Qua X, Metz RP, Porter WW, Cassone VM, Earnest DJ. Disruption of period gene expression alters the inductive effects of dioxin on the AhR signaling pathway in the mouse liver. Toxicol Appl Pharmacol 2009; 234(3): 370-7.
263. [263] Tavano F, di Mola FF, Latiano A, et al. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. J Crohns Colitis 2012; 6: 563-70.
264. [264] Chang TK, Chen J, Yang G, Yeung EY. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J Pineal Res 2010; 48: 55-64.
265. [265] Singh NP, Singh UP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Activation of aryl hydrocarbon receptor (AHR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS One 2011; 6: e23522.
266. [266] Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009; 206(1): 43-9.
267. [267] Liu JH, Wu ZF, Sun J, Jiang L, Jiang S, Fu WB. Role of ACcAMP-PKA Cascade in Antidepressant Action of Electroacupuncture Treatment in Rats. Evid Based Complement Alternat Med 2012; 2012: 932414.
268. [268] Akahoshi E, Yoshimura S, Uruno S, Ishihara-Sugano M. Effect of dioxins on regulation of tyrosine hydroxylase gene expression by aryl hydrocarbon receptor: a neurotoxicology study. Environ Health 2009; 8: 24.
269. [269] Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate Jr CA. The Neurobiology of the Switch Process in Bipolar Disorder: a Review. J Clin Psychiatry 2010; 71(11): 1488-1501.
270. [270] Anderson G. Melatonin and Cognitive Deficits in Bipolar Disorder and Mild Cognitive Impairment. Psychother Psychosom 2012; 81: 244
271. [271] Murakami E, Iwata T, Hiwada K, Kokubu T. Brain glutathione and blood pressure control. J Cardiovasc Pharmacol. 1987; 10(Suppl 12): S112-5.
272. [272] Barbaro G, Di Lorenzo G, Soldini M, et al. Vagal system impairment in human immunodeficiency virus-positive patients with chronic hepatitis C: does hepatic glutathione deficiency have a pathogenetic role? Scand J Gastroenterol. 1997; 32(12): 1261-6.
273. [273] Rush AJ, Siefert SE. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Exp Neurol 2009; 219(1): 36-43.
274. [274] Mercanoglu G, Safran N, Uzun H, Eroglu L. Chronic emotional stress exposure increases infarct size in rats: the role of oxidative and nitrosative damage in response to sympathetic hyperactivity. Meth Find Exp Clin Pharmacol 2008; 30(10): 745-52.
275. [275] Maes M, Mihaylova I, Leunis JC. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 2006; 27(5): 615-21.
276. [276] Caruso C, Candore G, Cigna D, Colucci AT, Modica MA. Biological significance of soluble IL-2 receptor. Mediat Inflamm 1993; 2(1): 3-21.
277. [277] Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002; 7(10): 1107-14.
278. [278] Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro-and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009; 42(5): 182-8.
279. [279] Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.
280. [280] Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006; 6(8): 1298-304.
281. [281] Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16(7): 751-62.
282. [282] Maes M, Mihaylova I, Kubera M, Ringel K: Activation of cellmediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36(1): 169-75.
283. [283] Himmerich H, Milenovi S, Fulda S, et al. Regulatory T cells increased while IL-1 decreased during antidepressant therapy. J Psychiatr Res 2010; 44(15): 1052-7.
284. [284] Zunszain PA, Anacker C, Cattaneo A, et al. Interleukin-1_: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012; 37(4): 939-49.
285. [285] Maes M, Meltzer HY, Scharpé S, et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993; 49(2): 151-65.
286. [286] Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 702-21.
287. [287] Gabbay V, Klein RG, Katz Y, et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 2010; 51(8): 935-43
288. [288] Christen S, Peterhans E, Stocker R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc Natl Acad Sci USA. 1990; 87(7): 2506-10.
289. [289] Zmarowski A, Wu HQ, Brooks M, et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. EurJ Neurosci 2009; 29(3): 529-38.
290. [290] Mishra NC, Rir-sima-ah J, Boyd RT, et al. Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors. J Immunol 2010; 185(1): 588-96.
291. [291] Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012; 7(7): e42357.
292. [292] Ye Q, Ye L, Xu X, et al. Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1_signaling pathway. BMC Complement Altern Med 2012; 12: 82.
293. [293] D'Aquila P, Rose G, Panno ML, Passarino G, Bellizzi D. SIRT3 gene expression: a link between inherited mitochondrial DNA variants and oxidative stress. Gene 2012; 497(2): 323-9.
294. [294] Wichers MC, Maes M. The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29(1): 11-7.
295. [295] Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immunoinflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog NeuroPsPharm Bio Psychiatr 2013; 42: 101-14.
296. [296] Anderson G, Maes M. Schizophrenia: Linking prenatal infection to hypoNMDAr, Immune-inflammation, demyelination, susceptibility genes, IDO, neuroprogression and treatment. Prog NeuroPsPharm Bio Psychiatr 2013; 42: 5-19..
297. [297] Phillips LJ, McGorry PD, Garner B, et al. Stress, the hippocampus and the hypothalamic pituitary adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006; 40: 725-41.
298. [298] Rawdin BS, Mellon SH, Dhabhar FS, et al. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun. In press.
299. [299] Sunami E, Usuda K, Nishiyama Y, Otori T, Katsura K, Katayama Y. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med 2012; 51(10): 1187-93.
300. [300] Xu YQ, Zhang D, Jin T, et al. Diurnal variation of hepatic antioxidant gene expression in mice. PLoS One 2012; 7(8): e44237.
301. [301] Schmidt AJ, Heiser P, Hemmeter UM, Krieg JC, Vedder H. Effects of antidepressants on mRNA levels of antioxidant enzymes in human monocytic U-937 cells. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1567-73.
302. [302] Samuelsson M, Gerdin G, Ollinger K, Vrethem M. Taurine and glutathione levels in plasma before and after ECT treatment. Psychiatry Res 2012; 198(1): 53-7.
303. [303] Zafir A, Ara A, Banu N. Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(2): 220-8.
304. [304] Garg R, Kumar A. Possible role of citalopram and desipramine against sleep deprivation-induced anxiety like-behavior alterations and oxidative damage in mice. Indian J Exp Biol. 2008; 46(11): 770-6.
305. [305] Zafir A, Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 2007; 572(1): 23-31.
306. [306] Bilici M, Ozturk C, Dursun H, et al. Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. Dig Dis Sci 2009; 54(9): 1868-75.
307. [307] Kumar P, Kumar A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(1): 100-8.
308. [308] Payne ME, Steck SE, George RR, Steffens DC. Fruit, vegetable, and antioxidant intakes are lower in older adults with depression. J Acad Nutr Diet 2012; 112(12): 2022-7
309. [309] Magalhães PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011; 33(4): 374-8.
310. [310] Das P, Tanious M, Fritz K, et al. Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking Nacetyl-cysteine versus placebo. Aust N Z J Psychiatry 2013; 47(4): 347-54..
311. [311] Qian HR, Yang Y. Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin 2009; 30(7): 907-12.
312. [312] Posser T, Kaster MP, Baraúna SC, Rocha JB, Rodrigues AL, Leal RB. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. Eur J Pharmacol 2009; 602(1): 85-91.
313. [313] Siwek M, Dudek D, Paul IA, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 2009; 118(1-3): 187-95.
314. [314] Maes M, Vandoolaeghe E, Neels H, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997; 42(5): 349-58.
315. [315] Zhao Z, Wang W, Guo H, Zhou D. Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behav Brain Res 2008; 194(1): 108-13.
316. [316] Kamsler A, Avital A, Greenberger V, Segal M. Aged SOD overexpressing mice exhibit enhanced spatial memory while lacking hippocampal neurogenesis. Antioxid Redox Signal 2007; 9(2): 181-9.
317. [317] Liu J, Somera-Molina KC, Hudson RL, Dubocovich ML. Melatonin potentiates running wheel-induced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus. J Pineal Res 2013; 54(2): 222-31.
318. [318] Prozorovski T, Schulze-Topphoff U, Glumm R, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol 2008; 10(4): 385-94.
319. [319] Bambico FR, Belzung C. Novel Insights into Depression and Antidepressants: A Synergy Between Synaptogenesis and Neurogenesis? Curr Top Behav Neurosci 2013; 15: 243-91
320. [320] Evans J, Sun Y, McGregor A, Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology 2012; 63(8): 1315-26.
321. [321] Beyea MM, Heslop CL, Sawyez CG, et al. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem 2007; 282(8): 5207-16.
322. [322] Sacchetti P, Sousa KM, Hall AC, et al. Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. Cell Stem Cell 2009; 5(4): 409-19.
323. [323] Di Serio C, Cozzi A, Angeli I, et al. Kynurenic Acid Inhibits the Release of the Neurotrophic Fibroblast Growth Factor (FGF)-1 and Enhances Proliferation of Glia Cells, in vitro. Cellular Mol Neurobiol 2005; 25(6): 981-93
324. [324] Berk M, Kapczinski F, Andreazza AC, Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3): 804-17.
325. [325] Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75: 1662-6.
326. [326] McKinnon MC, Yucel K, Nazarov A, MacQueen GM: A metaanalysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34(1): 41-54.
327. [327] Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004; 161(11): 1957-66.
328. [328] Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brainderived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12(4): 447-58.
329. [329] Frank B, Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005; 17(4): 269-86.
330. [330] Anderson G, Ojalla J. Alzheimer’s and Seizures: Interleukin-18, Indoleamine 2,3-Dioxygenase and Quinolinic Acid. Int.J.Trytophan Res 2010: 3 169-73
331. [331] Lenze EJ, Miller AR, Munir ZB, Pornnoppadol C, North CS. Psychiatric symptoms endorsed by somatization disorder patients in a psychiatric clinic. Ann Clin Psychiatry 1999; 11(2): 73-9.
332. [332] Zhang W, Tingare A, Ng DC, et al. IP3-dependent intracellular Ca2+ release is required for cAMP-induced c-fos expression in hippocampal neurons. Biochem Biophys Res Commun 2012; 425(2): 450-5.
333. [333] Jang YS, Kang YJ, Kim TJ, Bae K. Temporal expression profiles of ceramide and ceramide-related genes in wild-type and mPer1/mPer2 double knockout mice. Mol Biol Rep 2012; 39(4): 4215-21.
334. [334] Kornhuber J, Medlin A, Bleich S, et al. High activity of acid sphingomyelinase in major depression. J Neural Transm 2005; 112(11): 1583-90.
335. [335] Kennedy LH, Sutter CH, Leon Carrion S, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated Production of Reactive Oxygen Species is an Essential Step in the Mechanism of Action to Accelerate Human Keratinocyte Differentiation. Toxicol Sci 2013; 132(1): 235-49
336. [336] Tsuji G, Takahara M, Uchi H, et al. Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes: the basis of its anti-inflammatory effect. J Invest Dermatol 2012; 132(1): 59-68.
337. [337] Lin X, Yang H, Zhou L, Guo Z. Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med 2011; 51(1): 97-106.
338. [338] Tang T, Lin X, Yang H, et al. Overexpression of antioxidant enzymes upregulates aryl hydrocarbon receptor expression via increased Sp1 DNA-binding activity. Free Radic Biol Med 2010; 49(3): 487-92.
339. [339] Kalthoff S, Ehmer U, Freiberg N, Manns MP, Strassburg CP. Interaction between oxidative stress sensor Nrf2 and xenobioticactivated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-glucuronosyltransferase 1A10. J Biol Chem 2010; 285(9): 5993-6002.
340. [340] Nannelli A, Rossignolo F, Tolando R, Rossato P, Longo V, Gervasi PG. Effect of beta-naphthoflavone on AhR-regulated genes (CYP1A1, 1A2, 1B1, 2S1, Nrf2, and GST) and antioxidant enzymes in various brain regions of pig. Toxicology 2009; 265(3): 69-79.
341. [341] Park JH, Mangal D, Frey AJ, Harvey RG, Blair IA, Penning TM. Aryl hydrocarbon receptor facilitates DNA strand breaks and 8-oxo-2'-deoxyguanosine formation by the aldo-keto reductase product benzo[a]pyrene-7,8-dione. J Biol Chem 2009; 284(43): 29725-34.
342. [342] Pinel-Marie ML, Sparfel L, Desmots S, Fardel O. Aryl hydrocarbon receptor-dependent induction of the NADPH oxidase subunit NCF1/p47 phox expression leading to priming of human macrophage oxidative burst. Free Radic Biol Med 2009; 47(6): 825-34.
343. [343] Traber MG, Mustacich DJ, Sullivan LC, Leonard SW, Ahern-Rindell A, Kerkvliet N. Vitamin E status and metabolism in adult and aged aryl hydrocarbon receptor null mice. J Nutr Biochem 2010; 21(12): 1193-9.
344. [344] Chang HJ, Park JS, Lee EK, et al. Ascorbic acid suppresses the 2,3,7,8-tetrachloridibenxo-p-dioxin (TCDD)-induced CYP1A1 ex pression in human HepG2 cells. Toxicol In vitro 2009; 23(4): 622-6.
345. [345] Niedbala W, Alves-Filho JC, Fukada SY, et al. Regulation of type 17 helper T-cell function by nitric oxide during inflammation. Proc Natl Acad Sci U S A 2011; 108(22): 9220-5.
346. [346] Kim SH, Lu HF, Alano CC. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One 2011; 6(3): e14731.
347. [347] Ferland CL, Schrader LA. Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins. Neuroscience 2011; 174: 104-14.
348. [348] Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007 Oct 12; 28(1): 91-106.
349. [349] Sol EM, Wagner SA, Weinert BT, et al. Proteomic investigations of lysine acetylation identify diverse substrates of mitochondrial deacetylase sirt3. PLoS One 2012; 7(12): e50545.
350. [350] Zhu Y, Park SH, Ozden O, et al. Exploring the electrostatic repulsion model in the role of Sirt3 in directing MnSOD acetylation status and enzymatic activity. Free Radic Biol Med 2012; 53(4): 828-33.
351. [351] Fritz KS, Galligan JJ, Smathers RL, et al. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol 2011; 24(5): 651-62.
352. [352] Zarkovic K. 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 2003; 24(4-5): 293-303.
353. [353] Ungerstedt JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003; 131(1): 48-52.
354. [354] Anglin RE, Mazurek MF, Tarnopolsky MA, Rosebush PI. The mitochondrial genome and psychiatric illness. Am J Med Genet B Neuropsychiatr Genet 2012; 159B(7): 749-59.
355. [355] Sequeira A, Martin MV, Rollins B, et al. Mitochondrial mutations and polymorphisms in psychiatric disorders. Front Genet 2012; 3: 103.
356. [356] Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005; 19(12): 1646-56.
357. [357] Jaeger LB, Dohgu S, Sultana R, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 2009; 23(4): 507-17.
358. [358] Liu W, Zhou C. Corticosterone reduces brain mitochondrial function and expression of mitofusin, BDNF in depression-like rodents regardless of exercise preconditioning. Psychoneuroendocrinology 2012; 37(7): 1057-70.
359. [359] Dominguez-Rodriguez A. Melatonin in cardiovascular disease. Expert Opin Investig Drugs 2012; 21(11): 1593-6.
360. [360] Andreasen JT, Redrobe JP, Nielsen EØ. Combined_7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol Biochem Behav. 2012; 100(3): 624-629.
361. [361] Fava M, Targum SD, Nierenberg AA, et al. An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): a possible role for neurogenesis in drug discovery. J Psychiatr Res 2012 ; 46(12): 1553-63.
362. [362] Bruno VA, Scacchi PA, Perez-Lloret S, Esquifino AI, Cardinali DP, Cutrera RA. Melatonin treatment counteracts the hyperthermic effect of lipopolysaccharide injection in the Syrian hamster. Neurosci Lett 2005; 389(3): 169-72.
363. [363] Dagyte G, Trentani A, Postema F, et al. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci Ther 2010; 16(4): 195-207.
364. [364] Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012; 21(10): 1503-22.
365. [365] Ribases M, Fernandez-Aranda F, Gratacos M, et al. Contribution of the serotoninergic system to anxious and depressive traits that may be partially responsible for the phenotypical variability of bulimia nervosa. J Psychiatr Res 2008; 42(1): 50-7.
366. [366] Furuya M, Kunishige K, Miyaoka T, et al. Augmentation with ramelteon to achieve remission in geriatric major depression. Psychiatry Clin Neurosci 2012; 66(1): 81-2.
367. [367] Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct 2012; 8: 61
368. [368] Espallergues J, Mamiya T, Vallée M, et al. The antidepressant-like effects of the 3_-hydroxysteroid dehydrogenase inhibitor trilostane in mice is related to changes in neuroactive steroid and monoamine levels. Neuropharmacology 2012; 62(1): 492-502.
369. [369] Shirayama Y, Muneoka K, Fukumoto M, et al. Infusions of allopregnanolone into the hippocampus and amygdala, but not into the nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus 2011; 21(10): 1105-13.
370. [370] D'Aquila PS, Canu S, Sardella M, Spanu C, Serra G, Franconi F. Dopamine is involved in the antidepressant-like effect of allopregnanolone in the forced swimming test in female rats. Behav Pharmacol 2010; 21(1): 21-8.
371. [371] Lucki NC, Li D, Sewer MB. Sphingosine-1-phosphate rapidly increases cortisol biosynthesis and the expression of genes involved in cholesterol uptake and transport in H295R adrenocortical cells. Mol Cell Endocrinol 2012; 348: 165-75
372. [372] Singh A, Kumar A. Possible GABAergic modulation in the protective effect of allopregnanolone on sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Methods Find Exp Clin Pharmacol 2008; 30(9): 681-9.
373. [373] Ryan J, Ancelin ML. Polymorphisms of estrogen receptors and risk of depression: therapeutic implications. Drugs 2012; 72(13): 1725-38.
374. [374] Spence RD, Hamby ME, Umeda E, et al. Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci U S A 2011; 108(21): 8867-72.
375. [375] Récamier-Carballo S, Estrada-Camarena E, Reyes R, Fernández-Guasti A. Synergistic effect of estradiol and fluoxetine in young adult and middle-aged female rats in two models of experimental depression. Behav Brain Res 2012; 233(2): 351-8.
376. [376] Heydarpour P, Salehi-Sadaghiani M, Javadi-Paydar M, et al. Estradiol reduces depressive-like behavior through inhibiting nitric oxide/cyclic GMP pathway in ovariectomized mice. Horm Behav 2013; 63(2): 361-9.
377. [377] Kilic FS, Ozatik Y, Kaygisiz B, Baydemir C, Erol K. Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats. Neurosciences (Riyadh) 2012; 17(1): 39-43.
378. [378] Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 2003; 18(1-4): 113-24.
379. [379] Almeida OP, Flicker L, Yeap BB, Alfonso H, McCaul K, Hankey GJ. Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2012; 2: e151.
380. [380] Wang Y, Yang F, Liu YF, Gao F, Jiang W. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett 2011; 499(2): 74-9.
381. [381] Fujita M, Hines CS, Zoghbi SS, et al. Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry 2012; 72(7): 548-54.
382. [382] Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D. Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery. Eur J Pharmacol 2012; 689(1-3): 125-31.
383. [383] Shalaby AM, Kamal SM. Effect of rolipram, a phosphodiesterase enzyme type-4 inhibitor, on_-amino butyric acid content of the frontal cortex in mice exposed to chronic mild stress. J Pharmacol Pharmacother 2012; 3(2): 132-7.
384. [384] Niu K, Hozawa A, Kuriyama S, et al. Green tea consumption is associated with depressive symptoms in the elderly. Am J Clin Nutr 2009; 90(6): 1615-22.
385. [385] Koh SH, Kim SH, Kwon H, et al. Phosphatidylinositol-3 kinase/Akt and GSK-3 mediated cytoprotective effect of epigallocatechin gallate on oxidative stress-injured neuronal-differentiated N18D3 cells. Neurotoxicology 2004; 25(5): 793-802.
386. [386] Zhu WL, Shi HS, Wei YM, et al. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol Res 2012; 65(1): 74-80.
387. [387] Han SG, Han SS, Toborek M, Hennig B. EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes. Toxicol Appl Pharmacol 2012; 261(2): 181-8.
388. [388] Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002; 33(8): 1097-105.
389. [389] Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA. Lipoic Acid Improves Mitochondrial Function in Nonalcoholic Steatosis Through the Stimulation of Sirtuin 1 and Sirtuin 3. Obesity (Silver Spring) 2012; 20(10): 1974-83.
390. [390] McCarty MF, Barroso-Aranda J, Contreras F 2009. The ‘‘rejuvenatory’’ impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-g coactivator-1a. Med Hypotheses 2009; 72: 29-33.
391. [391] Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 2009; 183: 5917-5927.
392. [392] Ogle WO, Speisman RB, Ormerod BK. Potential of treating agerelated depression and cognitive decline with nutraceutical approaches: a mini-review. Gerontology. 2013; 59(1): 23-31.
393. [393] Zhang L, Xu T, Wang S, et al. Curcumin produces antidepressant effects via activating MAPK/ERK-dependent brain-derived neurotrophic factor expression in the amygdala of mice. Behav Brain Res 2012; 235(1): 67-72.
394. [394] Mohammadi-Bardbori A, Bengtsson J, Rannug U, Rannug A, Wincent E. Quercetin, resveratrol, and curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). Chem Res Toxicol 2012; 25(9): 1878-84.
395. [395] Choi EJ, Kim T, Kim GH. Quercetin acts as an antioxidant and downregulates CYP1A1 and CYP1B1 against DMBA-induced oxidative stress in mice. Oncol Rep 2012; 28(1): 291-6.
396. [396] Mei X, Xu D, Xu S, Zheng Y, Xu S. Gastroprotective and antidepressant effects of a new zinc(II)-curcumin complex in rodent models of gastric ulcer and depression induced by stresses. Pharmacol Biochem Behav 2011; 99(1): 66-74